


What is claimed is:

1. A compound of Formula (I):





or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1, 2, 3, or 4;

p is 0, 1, 2, 3, or 4;

--- is a single or a double bond;



Z is CR² or N;

Ring moiety **A** is selected from C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl;

Ring moiety **B** is 4-10 membered heterocycloalkyl, wherein Ring moiety **B** is attached to the -NH- group of Formula (I) at a ring member of a saturated or partially saturated ring of said 4-10 membered heterocycloalkyl;

R¹ is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl, OR^{a1}, SR^{a1}, NHOR^{a1}, C(O)R^{b1}, C(O)NR^{c1}R^{d1}, C(O)NR^{c1}(OR^{a1}), C(O)OR^{a1}, OC(O)R^{b1}, OC(O)NR^{c1}R^{d1}, NR^{c1}R^{d1}, NR^{c1}NR^{c1}R^{d1}, NR^{c1}C(O)R^{b1}, NR^{c1}C(O)OR^{a1}, NR^{c1}C(O)NR^{c1}R^{d1}, C(=NR^{e1})R^{b1}, C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}C(=NR^{e1})R^{b1}, NR^{c1}S(O)NR^{c1}R^{d1}, NR^{c1}S(O)R^{b1}, NR^{c1}S(O)₂R^{b1}, NR^{c1}S(O)(=NR^{e1})R^{b1}, NR^{c1}S(O)₂NR^{c1}R^{d1}, S(O)R^{b1}, S(O)NR^{c1}R^{d1}, S(O)₂R^{b1}, S(O)₂NR^{c1}R^{d1}, OS(O)(=NR^{e1})R^{b1}, OS(O)₂R^{b1},

$S(O)(=NR^{cl})R^{bl}$, SF_5 , $P(O)R^{fl}R^{gl}$, $OP(O)(OR^{hl})(OR^{il})$, $P(O)(OR^{hl})(OR^{il})$, and $BR^{jl}R^{kl}$, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents;

each R^{al}, R^{cl}, and R^{dl} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents;

or, any R^{cl} and R^{dl} attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents;

each R^{bl} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents;

each R^{el} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{fl} and R^{gl} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10

membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{h1} and Rⁱ¹ is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{j1} and R^{k1} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; or any R^{j1} and R^{k1} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{1A} is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl, OR^{a11}, SR^{a11}, NHOR^{a11}, C(O)R^{b11}, C(O)NR^{c11}R^{d11}, C(O)NR^{c11}(OR^{a11}), C(O)OR^{a11}, OC(O)R^{b11}, OC(O)NR^{c11}R^{d11}, NR^{c11}R^{d11}, NR^{c11}NR^{c11}R^{d11}, NR^{c11}C(O)R^{b11}, NR^{c11}C(O)OR^{a11}, NR^{c11}C(O)NR^{c11}R^{d11}, C(=NR^{e11})R^{b11}, C(=NR^{e11})NR^{c11}R^{d11}, NR^{c11}C(=NR^{e11})NR^{c11}R^{d11}, NR^{c11}C(=NR^{e11})R^{b11}, NR^{c11}S(O)NR^{c11}R^{d11}, NR^{c11}S(O)R^{b11}, NR^{c11}S(O)₂R^{b11}, NR^{c11}S(O)(=NR^{e11})R^{b11}, NR^{c11}S(O)₂NR^{c11}R^{d11}, S(O)R^{b11}, S(O)NR^{c11}R^{d11}, S(O)₂R^{b11}, S(O)₂NR^{c11}R^{d11}, OS(O)(=NR^{e11})R^{b11}, OS(O)₂R^{b11}, S(O)(=NR^{e11})R^{b11}, SF₅, P(O)R^{f11}R^{g11}, OP(O)(OR^{h11})(ORⁱ¹¹), P(O)(OR^{h11})(ORⁱ¹¹), and BR^{j11}R^{k11}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1B} substituents;

each R^{a11}, R^{c11}, and R^{d11} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1B} substituents;

or, any R^{c11} and R^{d11} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R^{1B} substituents;

each R^{b11} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1B} substituents;

each R^{e11} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{f11} and R^{g11} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{h11} and Rⁱ¹¹ is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{j11} and R^{k11} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy;

or any R^{j11} and R^{k11} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{1B} is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl, OR^{a12}, SR^{a12}, NHOR^{a12}, C(O)R^{b12}, C(O)NR^{c12}R^{d12}, C(O)NR^{c12}(OR^{a12}), C(O)OR^{a12}, OC(O)R^{b12}, OC(O)NR^{c12}R^{d12}, NR^{c12}R^{d12}, NR^{c12}NR^{c12}R^{d12}, NR^{c12}C(O)R^{b12}, NR^{c12}C(O)OR^{a12}, NR^{c12}C(O)NR^{c12}R^{d12}, C(=NR^{e12})R^{b12}, C(=NR^{e12})NR^{c12}R^{d12}, NR^{c12}C(=NR^{e12})NR^{c12}R^{d12}, NR^{c12}C(=NR^{e12})R^{b12},

NR^{c12}S(O)NR^{c12}R^{d12}, NR^{c12}S(O)R^{b12}, NR^{c12}S(O)₂R^{b12}, NR^{c12}S(O)(=NR^{e12})R^{b12}, NR^{c12}S(O)₂NR^{c12}R^{d12}, S(O)R^{b12}, S(O)NR^{c12}R^{d12}, S(O)₂R^{b12}, S(O)₂NR^{c12}R^{d12}, OS(O)(=NR^{e12})R^{b12}, OS(O)₂R^{b12}, S(O)(=NR^{e12})R^{b12}, SF₅, P(O)R^{f12}R^{g12}, OP(O)(OR^{h12})(ORⁱ¹²), P(O)(OR^{h12})(ORⁱ¹²), and BR^{j12}R^{k12}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{a12}, R^{c12}, and R^{d12} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

or, any R^{c12} and R^{d12} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{b12} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{e12} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{f12} and R^{g12} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{h12} and R^{i12} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{j12} and R^{k12} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy;

or any R^{j12} and R^{k12} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

R^2 is independently selected from H, D, halo, CN, OH, NO₂, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, cyano-C₁₋₄ alkyl, HO-C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₃₋₄ cycloalkyl, thio, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, carbamyl, C₁₋₄ alkylcarbamyl, di(C₁₋₄ alkyl)carbamyl, carboxy, C₁₋₄ alkylcarbonyl, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonylamino, C₁₋₄ alkoxy carbonylamino, C₁₋₄ alkylaminocarbonyloxy, C₁₋₄ alkylsulfonylamino, aminosulfonyl, C₁₋₄ alkylaminosulfonyl, di(C₁₋₄ alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₄ alkylaminosulfonylamino, di(C₁₋₄ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₄ alkylaminocarbonylamino, and di(C₁₋₄ alkyl)aminocarbonylamino;

each R^3 is independently selected from H, D, halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, cyano-C₁₋₄ alkyl, HO-C₁₋₄ alkyl, C₁₋₃ alkoxy-C₁₋₄ alkyl, and C₃₋₄ cycloalkyl;

R^4 is selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl; wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^{4A} substituents;

each R^{4A} is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-

C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl, OR^{a41}, SR^{a41}, NHOR^{a41}, C(O)R^{b41}, C(O)NR^{c41}R^{d41}, C(O)NR^{c41}(OR^{a41}), C(O)OR^{a41}, OC(O)R^{b41}, OC(O)NR^{c41}R^{d41}, NR^{c41}R^{d41}, NR^{c41}NR^{c41}R^{d41}, NR^{c41}C(O)R^{b41}, NR^{c41}C(O)OR^{a41}, NR^{c41}C(O)NR^{c41}R^{d41}, C(=NR^{e41})R^{b41}, C(=NR^{e41})NR^{c41}R^{d41}, NR^{c41}C(=NR^{e41})NR^{c41}R^{d41}, NR^{c41}C(=NR^{e41})R^{b41}, NR^{c41}S(O)NR^{c41}R^{d41}, NR^{c41}S(O)R^{b41}, NR^{c41}S(O)₂R^{b41}, NR^{c41}S(O)(=NR^{e41})R^{b41}, NR^{c41}S(O)₂NR^{c41}R^{d41}, S(O)R^{b41}, S(O)NR^{c41}R^{d41}, S(O)₂R^{b41}, S(O)₂NR^{c41}R^{d41}, OS(O)(=NR^{e41})R^{b41}, OS(O)₂R^{b41}, S(O)(=NR^{e41})R^{b41}, SF₅, P(O)R^{f41}R^{g41}, OP(O)(OR^{h41})(ORⁱ⁴¹), P(O)(OR^{h41})(ORⁱ⁴¹), and BR^{j41}R^{k41}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{4B} substituents;

each R^{a41}, R^{c41}, and R^{d41} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{4B} substituents;

or, any R^{c41} and R^{d41} attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R^{4B} substituents;

each R^{b41} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{4B} substituents;

each R^{e41} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10

membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{f41} and R^{g41} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{h41} and Rⁱ⁴¹ is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{j41} and R^{k41} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy;

or any R^{j41} and R^{k41} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{4B} is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl, OR^{a42}, SR^{a42}, NHOR^{a42}, C(O)R^{b42}, C(O)NR^{c42}R^{d42}, C(O)NR^{c42}(OR^{a42}), C(O)OR^{a42}, OC(O)R^{b42}, OC(O)NR^{c42}R^{d42}, NR^{c42}R^{d42}, NR^{c42}NR^{c42}R^{d42}, NR^{c42}C(O)R^{b42}, NR^{c42}C(O)OR^{a42}, NR^{c42}C(O)NR^{c42}R^{d42}, C(=NR^{e42})R^{b42}, C(=NR^{e42})NR^{c42}R^{d42}, NR^{c42}C(=NR^{e42})NR^{c42}R^{d42}, NR^{c42}C(=NR^{e42})R^{b42}, NR^{c42}S(O)NR^{c42}R^{d42}, NR^{c42}S(O)R^{b42}, NR^{c42}S(O)₂R^{b42}, NR^{c42}S(O)(=NR^{e42})R^{b42}, NR^{c42}S(O)₂NR^{c42}R^{d42}, S(O)R^{b42}, S(O)NR^{c42}R^{d42}, S(O)₂R^{b42}, S(O)₂NR^{c42}R^{d42}, OS(O)(=NR^{e42})R^{b42}, OS(O)₂R^{b42}, S(O)(=NR^{e42})R^{b42}, SF₅, P(O)R^{f42}R^{g42}, OP(O)(OR^{h42})(ORⁱ⁴²), P(O)(OR^{h42})(ORⁱ⁴²), and BR^{j42}R^{k42}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{4C} substituents;

each R^{a42} , R^{c42} , and R^{d42} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{4C} substituents;

or, any R^{c42} and R^{d42} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R^{4C} substituents;

each R^{b42} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{4C} substituents;

each R^{e42} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{f42} and R^{g42} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{h42} and R^{i42} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{j42} and R^{k42} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy;

or any R^{j42} and R^{k42} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl;

each R^{4C} is independently selected from H, D, halo, CN, NO_2 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, 5-6 membered heteroaryl- C_{1-4} alkyl, OR^{a43} , SR^{a43} , $NHOR^{a43}$, $C(O)R^{b43}$, $C(O)NR^{c43}R^{d43}$, $C(O)NR^{c43}(OR^{a43})$, $C(O)OR^{a43}$, $OC(O)R^{b43}$, $OC(O)NR^{c43}R^{d43}$, $NR^{c43}R^{d43}$, $NR^{c43}NR^{c43}R^{d43}$, $NR^{c43}C(O)R^{b43}$, $NR^{c43}C(O)OR^{a43}$, $NR^{c43}C(O)NR^{c43}R^{d43}$, $C(=NR^{e43})R^{b43}$, $C(=NR^{e43})NR^{c43}R^{d43}$, $NR^{c43}C(=NR^{e43})NR^{c43}R^{d43}$, $NR^{c43}C(=NR^{e43})R^{b43}$, $NR^{c43}S(O)NR^{c43}R^{d43}$, $NR^{c43}S(O)R^{b43}$, $NR^{c43}S(O)_2R^{b43}$, $NR^{c43}S(O)(=NR^{e43})R^{b43}$, $NR^{c43}S(O)_2NR^{c43}R^{d43}$, $S(O)R^{b43}$, $S(O)NR^{c43}R^{d43}$, $S(O)_2R^{b43}$, $S(O)_2NR^{c43}R^{d43}$, $OS(O)(=NR^{e43})R^{b43}$, $OS(O)_2R^{b43}$, $S(O)(=NR^{e43})R^{b43}$, SF_5 , $P(O)R^{f43}R^{g43}$, $OP(O)(OR^{h43})(OR^{i43})$, $P(O)(OR^{h43})(OR^{i43})$, and $BR^{j43}R^{k43}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{a43} , R^{c43} , and R^{d43} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

or, any R^{c43} and R^{d43} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{b43} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-

6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{e43} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{f43} and R^{g43} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{h43} and Rⁱ⁴³ is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{j43} and R^{k43} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy;

or any R^{j43} and R^{k43} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R⁵ is independently selected from H, D, halo, NO₂, CN, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl, OR^{a5}, SR^{a5}, NHOR^{a5}, C(O)R^{b5}, C(O)NR^{c5}R^{d5}, C(O)NR^{c5}(OR^{a5}), C(O)OR^{a5}, OC(O)R^{b5}, OC(O)NR^{c5}R^{d5}, NR^{c5}R^{d5}, NR^{c5}NR^{c5}R^{d5}, NR^{c5}C(O)R^{b5}, NR^{c5}C(O)OR^{a5}, NR^{c5}C(O)NR^{c5}R^{d5}, C(=NR^{e5})R^{b5}, C(=NR^{e5})NR^{c5}R^{d5}, NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}, NR^{c5}C(=NR^{e5})R^{b5}, NR^{c5}S(O)NR^{c5}R^{d5}, NR^{c5}S(O)R^{b5}, NR^{c5}S(O)₂R^{b5}, NR^{c5}S(O)(=NR^{e5})R^{b5}, NR^{c5}S(O)₂NR^{c5}R^{d5}, S(O)R^{b5}, S(O)NR^{c5}R^{d5}, S(O)₂R^{b5}, S(O)₂NR^{c5}R^{d5}, OS(O)(=NR^{e5})R^{b5}, OS(O)₂R^{b5}, S(O)(=NR^{e5})R^{b5}, SF₅, P(O)R^{f5}R^{g5}, OP(O)(OR^{h5})(ORⁱ⁵), P(O)(OR^{h5})(ORⁱ⁵), and BR^{j5}R^{k5}; wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄

alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^{5A} substituents;

each R^{a5}, R^{c5}, and R^{d5} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5A} substituents;

or, any R^{c5} and R^{d5} attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R^{5A} substituents;

each R^{b5} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5A} substituents;

each R^{e5} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{f5} and R^{g5} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{h5} and Rⁱ⁵ is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^{j5} and R^{k5} is independently selected from OH, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;
 or any R^{j5} and R^{k5} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl;
 each R^{5A} is independently selected from H, D, halo, CN, NO_2 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, 5-10 membered heteroaryl- C_{1-4} alkyl, OR^{a51} , SR^{a51} , $NHOR^{a51}$, $C(O)R^{b51}$, $C(O)NR^{c51}R^{d51}$, $C(O)NR^{c51}(OR^{a51})$, $C(O)OR^{a51}$, $OC(O)R^{b51}$, $OC(O)NR^{c51}R^{d51}$, $NR^{c51}R^{d51}$, $NR^{c51}NR^{c51}R^{d51}$, $NR^{c51}C(O)R^{b51}$, $NR^{c51}C(O)OR^{a51}$, $NR^{c51}C(O)NR^{c51}R^{d51}$, $C(=NR^{e51})R^{b51}$, $C(=NR^{e51})NR^{c51}R^{d51}$, $NR^{c51}C(=NR^{e51})NR^{c51}R^{d51}$, $NR^{c51}C(=NR^{e51})R^{b51}$, $NR^{c51}S(O)NR^{c51}R^{d51}$, $NR^{c51}S(O)R^{b51}$, $NR^{c51}S(O)_2R^{b51}$, $NR^{c51}S(O)(=NR^{e51})R^{b51}$, $NR^{c51}S(O)_2NR^{c51}R^{d51}$, $S(O)R^{b51}$, $S(O)NR^{c51}R^{d51}$, $S(O)_2R^{b51}$, $S(O)_2NR^{c51}R^{d51}$, $OS(O)(=NR^{e51})R^{b51}$, $OS(O)_2R^{b51}$, $S(O)(=NR^{e51})R^{b51}$, SF_5 , $P(O)R^{f51}R^{g51}$, $OP(O)(OR^{h51})(OR^{i51})$, $P(O)(OR^{h51})(OR^{i51})$, and $BR^{j51}R^{k51}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5B} substituents;

each R^{a51} , R^{c51} , and R^{d51} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5B} substituents;

or, any R^{c51} and R^{d51} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R^{5B} substituents;

each R^{b51} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5B} substituents;

each R^{e51} is independently selected from H, OH, CN, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl;

each R^{f51} and R^{g51} are independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl;

each R^{h51} and R^{i51} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C_{3-10} cycloalkyl- C_{1-4} alkyl, 6-10 membered aryl- C_{1-4} alkyl, 4-10 membered heterocycloalkyl- C_{1-4} alkyl, and 5-10 membered heteroaryl- C_{1-4} alkyl;

each R^{j51} and R^{k51} is independently selected from OH, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

or any R^{j51} and R^{k51} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl;

each R^{5B} is independently selected from H, D, halo, CN, NO_2 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, 5-6 membered heteroaryl- C_{1-4} alkyl, OR^{a52} , SR^{a52} , $NHOR^{a52}$, $C(O)R^{b52}$, $C(O)NR^{c52}R^{d52}$, $C(O)NR^{c52}(OR^{a52})$, $C(O)OR^{a52}$, $OC(O)R^{b52}$, $OC(O)NR^{c52}R^{d52}$, $NR^{c52}R^{d52}$, $NR^{c52}NR^{c52}R^{d52}$, $NR^{c52}C(O)R^{b52}$, $NR^{c52}C(O)OR^{a52}$, $NR^{c52}C(O)NR^{c52}R^{d52}$, $C(=NR^{e52})R^{b52}$, $C(=NR^{e52})NR^{c52}R^{d52}$, $NR^{c52}C(=NR^{e52})NR^{c52}R^{d52}$, $NR^{c52}C(=NR^{e52})R^{b52}$, $NR^{c52}S(O)NR^{c52}R^{d52}$, $NR^{c52}S(O)R^{b52}$, $NR^{c52}S(O)_2R^{b52}$, $NR^{c52}S(O)(=NR^{e52})R^{b52}$, $NR^{c52}S(O)_2NR^{c52}R^{d52}$, $S(O)R^{b52}$, $S(O)NR^{c52}R^{d52}$, $S(O)_2R^{b52}$, $S(O)_2NR^{c52}R^{d52}$,

OS(O)(=NR^{e52})R^{b52}, OS(O)₂R^{b52}, S(O)(=NR^{e52})R^{b52}, SF₅, P(O)R^{f52}R^{g52}, OP(O)(OR^{h52})(ORⁱ⁵²), P(O)(OR^{h52})(ORⁱ⁵²), and BR^{j52}R^{k52}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5C} substituents;

each R^{a52}, R^{c52}, and R^{d52} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5C} substituents;

or, any R^{c52} and R^{d52} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R^{5C} substituents;

each R^{b52} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5C} substituents;

each R^{e52} is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{f52} and R^{g52} are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{h52} and Rⁱ⁵² is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered

heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^{j52} and R^{k52} is independently selected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy;

or any Rⁱ⁵² and R^{k52} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{5C} is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl, OR^{a53}, SR^{a53}, NHOR^{a53}, C(O)R^{b53}, C(O)NR^{c53}R^{d53}, C(O)NR^{c53}(OR^{a53}), C(O)OR^{a53}, OC(O)R^{b53}, OC(O)NR^{c53}R^{d53}, NR^{c53}R^{d53}, NR^{c53}NR^{c53}R^{d53}, NR^{c53}C(O)R^{b53}, NR^{c53}C(O)OR^{a53}, NR^{c53}C(O)NR^{c53}R^{d53}, C(=NR^{e53})R^{b53}, C(=NR^{e53})NR^{c53}R^{d53}, NR^{c53}C(=NR^{e53})NR^{c53}R^{d53}, NR^{c53}C(=NR^{e53})R^{b53}, NR^{c53}S(O)NR^{c53}R^{d53}, NR^{c53}S(O)R^{b53}, NR^{c53}S(O)₂R^{b53}, NR^{c53}S(O)(=NR^{e53})R^{b53}, NR^{c53}S(O)₂NR^{c53}R^{d53}, S(O)R^{b53}, S(O)NR^{c53}R^{d53}, S(O)₂R^{b53}, S(O)₂NR^{c53}R^{d53}, OS(O)(=NR^{e53})R^{b53}, OS(O)₂R^{b53}, S(O)(=NR^{e53})R^{b53}, SF₅, P(O)R^{f53}R^{g53}, OP(O)(OR^{h53})(ORⁱ⁵³), P(O)(OR^{h53})(ORⁱ⁵³), and BR^{j53}R^{k53}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{a53}, R^{c53}, and R^{d53} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

or, any R^{c53} and R^{d53} attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{b53} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^G substituents;

each R^{e53} is independently selected from H, OH, CN, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl;

each R^{f53} and R^{g53} are independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl;

each R^{h53} and R^{i53} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl;

each R^{j53} and R^{k53} is independently selected from OH, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

or any R^{j53} and R^{k53} attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl; and

each R^G is independently selected from OH, NO_2 , CN, halo, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, cyano- C_{1-3} alkyl, HO- C_{1-3} alkyl, C_{1-3} alkoxy- C_{1-3} alkyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy, C_{1-3} haloalkoxy, amino, C_{1-3} alkylamino, di(C_{1-3} alkyl)amino, thio, C_{1-3} alkylthio, C_{1-3} alkylsulfinyl, C_{1-3} alkylsulfonyl, carbamyl, C_{1-3} alkylcarbamyl, di(C_{1-3} alkyl)carbamyl, carboxy, C_{1-3} alkylcarbonyl, C_{1-3} alkoxycarbonyl, C_{1-3} alkylcarbonyloxy, C_{1-3} alkylcarbonylamino, C_{1-3} alkoxycarbonylamino, C_{1-3} alkylaminocarbonyloxy, C_{1-3} alkylsulfonylamino, aminosulfonyl, C_{1-3} alkylaminosulfonyl, di(C_{1-3} alkyl)aminosulfonyl, aminosulfonylamino, C_{1-3} alkylaminosulfonylamino, di(C_{1-3} alkyl)aminosulfonylamino, aminocarbonylamino, C_{1-3} alkylaminocarbonylamino, and di(C_{1-3} alkyl)aminocarbonylamino.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is independently selected from H, halo, CN, NO_2 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, 5-6 membered heteroaryl- C_{1-4} alkyl, OR^{a1} , SR^{a1} , $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, $NR^{c1}C(O)NR^{c1}R^{d1}$, $NR^{c1}S(O)_2R^{b1}$, $NR^{c1}S(O)_2NR^{c1}R^{d1}$, $S(O)_2R^{b1}$, and $S(O)_2NR^{c1}R^{d1}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is independently selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-3} alkyl, phenyl- C_{1-3} alkyl, 4-7 membered heterocycloalkyl- C_{1-3} alkyl, 5-6 membered heteroaryl- C_{1-3} alkyl, OR^{a1} , SR^{a1} , and $NR^{c1}R^{d1}$, wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-3} alkyl, phenyl- C_{1-3} alkyl, 4-7 membered heterocycloalkyl- C_{1-3} alkyl, and 5-6 membered heteroaryl- C_{1-3} alkyl are each optionally substituted with 1 or 2 independently selected R^{1A} substituents.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is independently selected from H, C_{1-6} alkyl, phenyl, 5-7 membered heterocycloalkyl, OR^{a1} , SR^{a1} , and $NR^{c1}R^{d1}$, wherein said C_{1-6} alkyl, phenyl, and 5-7 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R^{1A} substituents.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is independently selected from H and OR^{a1} .

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein:

each R^{a1} , R^{c1} , and R^{d1} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7}

cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents;

each R^{b1} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1A} substituents;

each R^{1A} is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl, OR^{a11}, C(O)R^{b11}, C(O)NR^{c11}R^{d11}, C(O)OR^{a11}, OC(O)R^{b11}, OC(O)NR^{c11}R^{d11}, NR^{c11}R^{d11}, NR^{c11}C(O)R^{b11}, NR^{c11}C(O)OR^{a11}, NR^{c11}C(O)NR^{c11}R^{d11}, NR^{c11}S(O)₂R^{b11}, NR^{c11}S(O)₂NR^{c11}R^{d11}, S(O)₂R^{b11}, and S(O)₂NR^{c11}R^{d11}, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{1B} substituents;

each R^{a11}, R^{c11}, and R^{d11} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^{b11} is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{1B} is independently selected from H, D, and OR^{a12}; and

each R^{a12} is independently selected from H and C₁₋₆ alkyl.

7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein:

each R^{a1}, R^{c1}, and R^{d1} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 membered

heterocycloalkyl-C₁₋₃ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^{1A} substituents;

each R^{b1} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₂ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₂ alkyl, which are each optionally substituted with 1 or 2 independently selected R^{1A} substituents; and

each R^{1A} is independently selected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^{a11}, and C(O)OR^{a11}, wherein said C₁₋₆ alkyl, and C₁₋₆ haloalkyl, are each optionally substituted with 1, 2, or 3 independently selected R^{1B} substituents;

each R^{a11} is independently selected from H and C₁₋₄ alkyl, wherein said C₁₋₄ alkyl is optionally substituted by 1, 2, or 3 independently selected R^{1B} substituents; and

each R^{1B} is independently selected from H, D, and O-C₁₋₄ alkyl.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is OR^{a1} and R^{a1} is C₁₋₃ alkyl.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R² is selected from H, halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, cyano-C₁₋₄ alkyl, HO-C₁₋₄ alkyl, C₁₋₃ alkoxy-C₁₋₄ alkyl, and C₃₋₄ cycloalkyl.

10. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R² is H or halo.

11. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R² is H or F.

12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein Ring moiety **B** is monocyclic 4-7 membered heterocycloalkyl.

13. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein Ring moiety **B** is piperidinyl.

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein each R^3 is independently selected from H, F, and methyl.
16. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein each R^3 is independently selected from H and methyl.
17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl; wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-7} cycloalkyl- C_{1-4} alkyl, phenyl- C_{1-4} alkyl, 4-7 membered heterocycloalkyl- C_{1-4} alkyl, and 5-6 membered heteroaryl- C_{1-4} alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^{4A} substituents.
18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl- C_{1-4} alkyl; wherein said C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl- C_{1-4} alkyl are each optionally substituted by 1 or 2 independently selected R^{4A} substituents.
19. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl- C_{1-4} alkyl; wherein said C_{1-6} alkyl, C_{3-6} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R^{4A} substituents.

20. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R^4 is C_{1-6} alkyl and C_{3-6} cycloalkyl.

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein:

each R^{4A} is independently selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-4} cycloalkyl, OR^{a41} , $C(O)R^{b41}$, $C(O)NR^{c41}R^{d41}$, $C(O)OR^{a41}$, $OC(O)R^{b41}$, $OC(O)NR^{c41}R^{d41}$, $NR^{c41}R^{d41}$, $NR^{c41}C(O)R^{b41}$, $NR^{c41}C(O)OR^{a41}$, $NR^{c41}C(O)NR^{c41}R^{d41}$, $NR^{c41}S(O)_2R^{b41}$, $NR^{c41}S(O)_2NR^{c41}R^{d41}$, $S(O)_2R^{b41}$, and $S(O)_2NR^{c41}R^{d41}$, wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{3-4} cycloalkyl are each optionally substituted with 1, 2, or 3 independently selected R^{4B} substituents;

each R^{a41} , R^{c41} , and R^{d41} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{3-4} cycloalkyl, wherein said C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{3-4} cycloalkyl are each optionally substituted with 1 or 2 independently selected R^{4B} substituents;

each R^{b41} is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{3-4} cycloalkyl, which are each optionally substituted with 1 or 2 independently selected R^{4B} substituents;

each R^{4B} is independently selected from H, halo, CN, C_{1-3} alkyl, C_{1-3} haloalkyl, OR^{a42} , and $NR^{c42}R^{d42}$;

each R^{a42} , R^{c42} , and R^{d42} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each R^{b42} is independently selected from C_{1-3} alkyl and C_{1-3} haloalkyl.

22. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein:

each R^{4A} is independently selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-4} cycloalkyl, OR^{a41} , $C(O)R^{b41}$, $C(O)NR^{c41}R^{d41}$, $C(O)OR^{a41}$, $OC(O)R^{b41}$, $OC(O)NR^{c41}R^{d41}$, $NR^{c41}R^{d41}$, $NR^{c41}C(O)R^{b41}$, $NR^{c41}C(O)OR^{a41}$, $NR^{c41}C(O)NR^{c41}R^{d41}$, $NR^{c41}S(O)_2R^{b41}$, $NR^{c41}S(O)_2NR^{c41}R^{d41}$, $S(O)_2R^{b41}$, and $S(O)_2NR^{c41}R^{d41}$;

each R^{a41} , R^{c41} , and R^{d41} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each R^{b41} is independently selected from C_{1-3} alkyl and C_{1-3} haloalkyl.

23. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein:
- each R^{4A} is independently selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, OR^{a41} , and $NR^{c41}R^{d41}$;
- each R^{a41} , R^{c41} , and R^{d41} is independently selected from H and C_{1-3} alkyl, and C_{1-3} haloalkyl; and
- each R^{b41} is independently C_{1-3} alkyl.
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Ring moiety **A** is 5-10 membered heteroaryl.
25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Ring moiety **A** is 5-6 membered heteroaryl.
26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Ring moiety **A** is 1H-pyrrolo[2,3-b]pyridinyl, pyridinyl, or pyrazolyl.
27. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Ring moiety **A** is pyrazolyl.
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein p is 0 or 1.
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each R^5 is independently selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-4} cycloalkyl, OR^{a5} , and $NR^{c5}R^{d5}$; and each R^{a5} , R^{c5} , and R^{d5} is independently selected from H, C_{1-6} alkyl, and C_{1-6} haloalkyl.
30. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein each R^5 is independently selected from CH_3 or NH_2 .
31. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
- n is 0, 1, or 2;

p is 0, 1, or 2;

Ring moiety **A** is selected from C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl;

Ring moiety **B** is azetidiny, pyrrolidinyl or piperidinyl;

R¹ is H, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, phenyl-C₁₋₃ alkyl, 4-7 membered heterocycloalkyl-C₁₋₃ alkyl, 5-6 membered heteroaryl-C₁₋₃ alkyl, OR^{a1}, SR^{a1}, and NR^{c1}R^{d1}, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, phenyl-C₁₋₃ alkyl, 4-7 membered heterocycloalkyl-C₁₋₃ alkyl, and 5-6 membered heteroaryl-C₁₋₃ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^{1A} substituents;

each R^{a1}, R^{c1}, and R^{d1} is independently selected from H, D, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, and C₃₋₇ cycloalkyl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, and C₃₋₇ cycloalkyl-C₁₋₄ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^{1A} substituents;

each R^{1A} is independently selected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^{a11}, C(O)R^{b11}, C(O)NR^{c11}R^{d11}, C(O)OR^{a11}, OC(O)R^{b11}, OC(O)NR^{c11}R^{d11}, NR^{c11}R^{d11}, NR^{c11}C(O)R^{b11}, NR^{c11}C(O)OR^{a11}, NR^{c11}C(O)NR^{c11}R^{d11}, NR^{c11}S(O)₂R^{b11}, NR^{c11}S(O)₂NR^{c11}R^{d11}, S(O)₂R^{b11}, and S(O)₂NR^{c11}R^{d11}, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted by 1, 2, or 3 independently selected R^{1B} substituents;

each R^{a11}, R^{c11}, and R^{d11} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^{b11} is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^{1B} is independently selected from H, D, and OR^{a12};

each R^{a12} is independently selected from H and C₁₋₆ alkyl;

R² is selected from H, halo, CN, C₁₋₃ alkyl, and C₁₋₃ haloalkyl;

each R³ is independently selected from H, halo, C₁₋₃ alkyl, and cyclopropyl;

R⁴ is selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C₁₋₄ alkyl; wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered

heterocycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C₁₋₄ alkyl are each optionally substituted by 1 or 2 independently selected R^{4A} substituents;

each R^{4A} is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^{a41}, C(O)R^{b41}, C(O)NR^{c41}R^{d41}, C(O)OR^{a41}, OC(O)R^{b41}, OC(O)NR^{c41}R^{d41}, NR^{c41}R^{d41}, NR^{c41}C(O)R^{b41}, NR^{c41}C(O)OR^{a41}, NR^{c41}C(O)NR^{c41}R^{d41}, NR^{c41}S(O)₂R^{b41}, NR^{c41}S(O)₂NR^{c41}R^{d41}, S(O)₂R^{b41}, and S(O)₂NR^{c41}R^{d41}, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted with 1, 2, or 3 independently selected R^{4B} substituents;

each R^{a41}, R^{c41}, and R^{d41} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted with 1 or 2 independently selected R^{4B} substituents;

each R^{b41} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, which are each optionally substituted with 1 or 2 independently selected R^{4B} substituents;

each R^{4B} is independently selected from H, halo, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, OR^{a42}, and NR^{c42}R^{d42};

each R^{a42}, R^{c42}, and R^{d42} is independently selected from H, C₁₋₃ alkyl, and C₁₋₃ haloalkyl;

each R^{b42} is independently selected from C₁₋₃ alkyl and C₁₋₃ haloalkyl.

each R⁵ is independently selected from H, halo, NO₂, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl, OR^{a5}, SR^{a5}, NHOR^{a5}, C(O)R^{b5}, C(O)NR^{c5}R^{d5}, C(O)OR^{a5}, OC(O)R^{b5}, OC(O)NR^{c5}R^{d5}, NR^{c5}R^{d5}, NR^{c5}C(O)R^{b5}, NR^{c5}C(O)OR^{a5}, NR^{c5}C(O)NR^{c5}R^{d5}, NR^{c5}S(O)₂R^{b5}, NR^{c5}S(O)₂NR^{c5}R^{d5}, S(O)₂R^{b5}, and S(O)₂NR^{c5}R^{d5}; wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^{5A} substituents;

each R^{a5}, R^{c5}, and R^{d5} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,

phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5A} substituents; and

each R^{b5} is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R^{5A} substituents.

each R^{5A} is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^{a51}, SR^{a51}, NHOR^{a51}, C(O)R^{b51}, C(O)NR^{c51}R^{d51}, C(O)OR^{a51}, OC(O)R^{b51}, OC(O)NR^{c51}R^{d51}, NR^{c51}R^{d51}, NR^{c51}C(O)R^{b51}, NR^{c51}C(O)OR^{a51}, NR^{c51}C(O)NR^{c51}R^{d51}, NR^{c51}S(O)₂R^{b51}, NR^{c51}S(O)₂NR^{c51}R^{d51}, S(O)₂R^{b51}, and S(O)₂NR^{c51}R^{d51};

each R^{a51}, R^{c51}, and R^{d51} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^{b51} is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.

32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
 n is 0 or 1;
 p is 0 or 1;
 Ring moiety **A** is 5-10 membered heteroaryl having 1 or 2 N ring forming atoms;
 Ring moiety **B** is piperidinyl;
 R¹ is independently selected from H, C₁₋₆ alkyl, phenyl, 5-7 membered heterocycloalkyl, OR^{a1}, SR^{a1}, and NR^{c1}R^{d1}, wherein said C₁₋₆ alkyl, phenyl, and 5-7 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R^{1A} substituents;

each R^{a1}, R^{c1}, and R^{d1} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl are each optionally substituted with 1, 2, or 3 independently selected R^{1A} substituents;

each R^{1A} is independently selected from D, halo, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₄ cycloalkyl, OR^{a11}, and C(O)OR^{a11}, wherein said C₁₋₆ alkyl, and C₁₋₆ haloalkyl are each optionally substituted with 1, 2, or 3 independently selected R^{1B} substituents;

each R^{a11} is independently selected from H and C₁₋₄ alkyl, wherein said C₁₋₄ alkyl is optionally substituted by 1, 2, or 3 independently selected R^{1B} substituents;

each R^{1B} is independently selected from H, D, and O-C₁₋₄ alkyl;

R² is H or F;

each R³ is independently selected from H or methyl;

R⁴ is selected from C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C₁₋₄ alkyl; wherein said C₁₋₆ alkyl, C₃₋₆ cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C₁₋₄ alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^{4A} substituents;

each R^{4A} is independently selected from H, C₁₋₆ alkyl, OH, and NR^{c41}R^{d41};

each R^{c41} and R^{d41} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R⁵ is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^{a5}, and NR^{c5}R^{d5}; and

each R^{a5}, R^{c5}, and R^{d5} is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl.

33. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

n is 0 or 1;

p is 0 or 1;

Ring moiety **A** is 5-10 membered heteroaryl having 1 or 2 N ring forming atoms;

Ring moiety **B** is piperidinyl;

R¹ is independently selected from H and OR^{a1};

each R^{a1} is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl are each optionally substituted with 1 or 2 independently selected R^{1A} substituents;

each R^{1A} is independently selected from C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₄ cycloalkyl, OH, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

R² is H or F;

each R³ is independently selected from H or methyl;





R^4 is selected from C_{1-6} alkyl and C_{3-6} cycloalkyl; wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R^{4A} substituents;

each R^{4A} is independently selected from H and C_{1-6} alkyl;

each R^5 is independently selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-4} cycloalkyl, OR^{a5} , and $NR^{c5}R^{d5}$; and





each R^{a5} , R^{c5} , and R^{d5} is independently selected from H, C_{1-6} alkyl, and C_{1-6} haloalkyl.

34. The compound of any one of claims 1-33, having Formula (Va), or (Vb), or (Vc), or (Vd):





or a pharmaceutically acceptable salt of any of the aforementioned.


35. The compound of any one of claims 1-33, having Formula (VIa), or (VIIa), or (VIIIa), or (IXa):



or a pharmaceutically acceptable salt of any of the aforementioned.




36. The compound of any one of claims 1-33, having Formula (VIb), or (VIIIb), or (IXb):





or a pharmaceutically acceptable salt of any of the aforementioned.

37. The compound of any one of claims 1-33, having Formula (VIc), or (VIIIc), or (IXc):



or a pharmaceutically acceptable salt of any of the aforementioned.

38. The compound of claim 1, selected from:

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-ethoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-isobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-(cyclopropylmethoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-(2-methoxyethoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

6-fluoro-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

8-(2,2-difluoroethoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-((tetrahydrofuran-3-yl)methoxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-ethoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-1-(cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-8-ethoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-isopropoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-isobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrrolo[2,3-*b*]pyridin-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine; and

7-(2-aminopyridin-4-yl)-8-isobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1, selected from:

8-ethoxy-7-(3-methyl-1*H*-pyrazol-4-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

Methyl 4-((2-((1-(methylsulfonyl)piperidin-4-yl)amino)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-8-yl)oxy)piperidine-1-carboxylate;

(*R*)-1-(2-(((3*R*,4*S*)-4-((8-ethoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-yl)amino)-3-methylpiperidin-1-yl)sulfonyl)ethyl)pyrrolidin-3-ol;

8-ethoxy-*N*-((3*R*,4*S*)-3-methyl-1-((1-methyl-1*H*-pyrazol-4-yl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-ethoxy-*N*-((3*R*,4*S*)-3-methyl-1-((2-methyl-2*H*-1,2,3-triazol-4-yl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-8-phenyl-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-(4-fluoropiperidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

*N*²-(1-(methylsulfonyl)piperidin-4-yl)-*N*⁸-phenyl-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridine-2,8-diamine;

8-(4-fluorophenyl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-ethoxy-*N*-((3*R*,4*S*)-3-methyl-1-((3-(piperidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-1-((3-(dimethylamino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-ethoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-ethoxy-*N*-((3*R*,4*S*)-3-methyl-1-((3-(pyrrolidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-(4-(trifluoromethyl)piperidin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-(3-fluoropiperidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-Ethoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-(4-methylpiperidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

2-fluoro-4-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-8-yl)benzonitrile;

N-(1-(methylsulfonyl)piperidin-4-yl)-8-propyl-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-((2-(pyrrolidin-1-yl)ethyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-((4,4-difluorocyclohexyl)oxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-((tetrahydrofuran-3-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-(ethoxy-*ds*)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

8-Isobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-(2,2-difluoroethoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-(3,3,3-trifluoropropoxy)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-Butoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-8-propoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-8-(piperidin-1-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-(3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-8-(piperidin-1-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-(4-(2-Methoxyethyl)piperazin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-8-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((3-(Ethyl(methyl)amino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((3-(Dimethylamino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-Isopropoxy-*N*-((3*R*,4*S*)-1-((3-(isopropyl(methyl)amino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-Isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-((3-(piperidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-Isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-((3-(pyrrolidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((3-(Diethylamino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-Isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-((3-(4-methylpiperazin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((3-(4-Ethylpiperazin-1-yl)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

8-Isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-((4-morpholinobutyl)sulfonyl)piperidin-4-yl)-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((4-((2,2-Difluoroethyl)amino)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((4-(Ethyl(methyl)amino)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((4-(Dimethylamino)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

N-((3*R*,4*S*)-1-((4-((*R*)-3-(Difluoromethyl)pyrrolidin-1-yl)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*c*]pyrimidin-2-amine;

5-Isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-Cyclobutoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-Isobutoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-(2,2-Difluoroethoxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-(2,2,3,3-tetrafluoropropoxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-Cyclopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-((3,3-Difluorocyclopentyl)oxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-(Cyclobutylmethoxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-(Cyclopentylmethoxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-Isobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-(2,2-Difluoroethoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-(2,2,3,3-tetrafluoropropoxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-(Cyclopropylmethoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-5-(piperidin-1-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-5-(piperidin-1-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-((1-methyl-1*H*-imidazol-4-yl)sulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-Isopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Cyclobutoxy-*N*-((3*R*,4*S*)-1-(ethylsulfonyl)-3-methylpiperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Cyclobutoxy-*N*-((3*R*,4*S*)-3-methyl-1-((1-methyl-1*H*-pyrazol-4-yl)sulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Cyclobutoxy-*N*-((3*R*,4*S*)-3-methyl-1-((1-methyl-1*H*-imidazol-4-yl)sulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-((1-methyl-1*H*-pyrazol-4-yl)sulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyridin-2-amine;

5-Cyclobutoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Isobutoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Butoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Isobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Butoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-(3-methylcyclobutoxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(3-(Difluoromethyl)cyclobutoxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Cyclopropoxy-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-((4,4-Difluorocyclohexyl)oxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((3-methyltetrahydro-2*H*-pyran-4-yl)oxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((2-methyltetrahydro-2*H*-pyran-4-yl)oxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((2-(trifluoromethyl)tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((1-(trifluoromethyl)cyclobutyl)methoxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(Cyclopropylmethoxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(Isopentyloxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Cyclobutoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(3,3-Difluorocyclobutoxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((2-(trifluoromethyl)tetrahydro-2*H*-pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-((1-(trifluoromethyl)cyclobutyl)methoxy)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(Isopentyloxy)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Ethoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(Ethylthio)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(Isopropylthio)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(3,3-Difluoropiperidin-1-yl)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

(*R*)-5-(3-Fluoropiperidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

(*S*)-5-(3-Fluoropiperidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(3,3-Difluoropyrrolidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(2-Azabicyclo[2.2.1]heptan-2-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

(*S*)-5-(2-Methylpiperidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

(*S*)-5-(2-Methylpyrrolidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

(*S*)-5-(3-(Difluoromethyl)pyrrolidin-1-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(7-Azabicyclo[2.2.1]heptan-7-yl)-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-(1-(Methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-5-(3-(trifluoromethyl)piperidin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-2-*d*)oxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-1,1,1,3,3,3-*d*₆)oxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

N-((3*R*,4*S*)-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-*d*₇)oxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-(Cyclopentyloxy)-*N*-((3*R*,4*S*)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

5-Isopropoxy-*N*-(1-(methylsulfonyl)piperidin-4-yl)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine; and

N-(1-(Methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-2-*d*)oxy)-6-(1*H*-pyrazol-4-yl)-[1,2,4]triazolo[1,5-*a*]pyrazin-2-amine;

or a pharmaceutically acceptable salt thereof.

40. A pharmaceutical composition comprising the compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

41. A method of inhibiting CDK2, comprising contacting the CDK2 with the compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof.

42. A method of inhibiting CDK2 in a patient, comprising administering to the patient a compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof.
43. A method of treating a disease or disorder associated with CDK2 in a patient, comprising administering to the patient a therapeutically effective amount of the compound of any one of claims 1-39, or pharmaceutically acceptable salt thereof.
44. The method of claim 43, wherein the disease or disorder is associated with an amplification of the cyclin E1 (CCNE1) gene and/or overexpression of CCNE1.
45. A method of treating a human subject having a disease or disorder associated with cyclin-dependent kinase 2 (CDK2), comprising administering to the human subject a compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, wherein the human subject has been previously determined to:
- (i)
 - (a) have a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1; and/or
 - (b) have a cyclin dependent kinase inhibitor 2A (CDKN2A) gene lacking one or more inactivating nucleic acid substitutions and/or deletions;
 - (ii)
 - (a) have an amplification of the cyclin E1 (CCNE1) gene; and/or
 - (b) have an expression level of CCNE1 in a biological sample obtained from the human subject that is higher than a control expression level of CCNE1.
46. A method of treating a human subject having a disease or disorder associated with cyclin-dependent kinase 2 (CDK2), comprising:
- (i) identifying, in a biological sample obtained from the human subject:
 - (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1; and/or
 - (b) a cyclin dependent kinase inhibitor 2A (CDKN2A) gene lacking one or more inactivating nucleic acid substitutions;
 - (ii) identifying, in a biological sample obtained from the human subject:
 - (a) an amplification of the cyclin E1 (CCNE1) gene; and/or

- (b) an expression level of CCNE1 that is higher than a control expression level of CCNE1; and
- (iii) administering a compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, to the human subject.

47. The method of claim 46, comprising:

- (i) identifying, in a biological sample obtained from the human subject:
 - (a) a nucleotide sequence encoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1; and/or
 - (b) a CDKN2A gene lacking one or more inactivating nucleic acid substitutions and/or deletions;
- (ii) identifying, in a biological sample obtained from the human subject:
 - (a) an amplification of the CCNE1 gene; and
- (iii) administering the compound or the salt to the human subject.

48. A method of evaluating the response of a human subject having a disease or disorder associated with cyclin-dependent kinase 2 (CDK2) to a compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, comprising:

- (a) administering the compound or the salt, to the human subject, wherein the human subject has been previously determined to have an amplification of the cyclin E1 (CCNE1) gene and/or an expression level of CCNE1 that is higher than a control expression level of CCNE1;

- (b) measuring, in a biological sample of obtained from the subject subsequent to the administering of step (a), the level of retinoblastoma (Rb) protein phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3,

wherein a reduced level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3, as compared to a control level of Rb phosphorylation at the serine corresponding to amino acid position 780 of SEQ ID NO:3, is indicative that the human subject responds to the compound or the salt.

49. The method of any one of claims 43-48, wherein the disease or disorder is cancer.